The rapid increase in total payments for GLDs may not reflect the change in actual economic burden, because a growing portion of the total payments were returned to the payers in the form of manufacturer rebates. This study explored trends in rebates for GLDs from 2010-17. We defined total payments as the retail amount the pharmacy received, including two components:
1) rebates, the estimated proportion of the total payments retroactively passed through to pharmacy benefit managers and the payers; and
2) net payments, the net spending for the GLDs. We used data from the 2010-17 Medical Expenditure Panel Survey to estimate the total payments including out-of-pocket payments, and data from the SSR Health and Medicaid programs to estimate the net payments and rebates.
Y.Ding: None. L.Shi: None. Y.Lin: None. H.Shao: Board Member; BRAVO4HEALTH, LLC.